Stock Scorecard
Stock Summary for 4D Molecular Therapeutics Inc (FDMT) - $9.21 as of 11/20/2024 4:03:21 PM EST
Total Score
12 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for FDMT
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for FDMT
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for FDMT
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for FDMT
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for FDMT (26 out of 90)
Stock Price Rating (Max of 10) | 4 |
Historical Stock Price Rating (Max of 10) | 1 |
Stock Price Trend (Max of 10) | 0 |
Book Value (Max of 10) | 4 |
Book Value to Price (Max of 10) | 1 |
Analyst Buy Ratings (Max of 5) | 5 |
Analyst Strong Buy Ratings (Max of 5) | 5 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 0 |
Trading Volume (Max of 10) | 6 |
Price to Earnings (Max of 10) | 0 |
Latest News for for FDMT
Financial Details for FDMT
Company Overview |
|
---|---|
Ticker | FDMT |
Company Name | 4D Molecular Therapeutics Inc |
Country | USA |
Description | 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors. The company is headquartered in Emeryville, California. |
Sector Name | LIFE SCIENCES |
Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
Most Recent Quarter | 9/30/2024 |
Next Earnings Date | N/A |
Stock Price History |
|
Last Day Price | 9.21 |
Price 4 Years Ago | 0.00 |
Last Day Price Updated | 11/20/2024 4:03:21 PM EST |
Last Day Volume | 652,199 |
Average Daily Volume | 812,767 |
52-Week High | 36.25 |
52-Week Low | 7.32 |
Last Price to 52 Week Low | 25.82% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 120.49 |
Sector PE | 40.32 |
5-Year Average PE | -7.03 |
Free Cash Flow Ratio | 0.85 |
Industry Free Cash Flow Ratio | 15.59 |
Sector Free Cash Flow Ratio | 27.97 |
Current Ratio Most Recent Quarter | 17.33 |
Total Cash Per Share | 10.86 |
Book Value Per Share Most Recent Quarter | 7.15 |
Price to Book Ratio | 0.73 |
Industry Price to Book Ratio | 5.50 |
Sector Price to Book Ratio | 20.88 |
Price to Sales Ratio Twelve Trailing Months | 23,576.13 |
Industry Price to Sales Ratio Twelve Trailing Months | 20.11 |
Sector Price to Sales Ratio Twelve Trailing Months | 7.11 |
Analyst Buy Ratings | 5 |
Analyst Strong Buy Ratings | 5 |
Share Statistics |
|
Total Shares Outstanding | 46,227,700 |
Market Capitalization | 425,757,117 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 6.19% |
Reported EPS 12 Trailing Months | -2.85 |
Reported EPS Past Year | -2.08 |
Reported EPS Prior Year | -2.64 |
Net Income Twelve Trailing Months | -143,480,000 |
Net Income Past Year | -100,837,000 |
Net Income Prior Year | -107,494,000 |
Quarterly Revenue Growth YOY | -100.00% |
5-Year Revenue Growth | 15.04% |
Operating Margin Twelve Trailing Months | -17,044.00 |
Balance Sheet |
|
Total Cash Most Recent Quarter | 501,892,000 |
Total Cash Past Year | 288,232,000 |
Total Cash Prior Year | 213,554,000 |
Net Cash Position Most Recent Quarter | 501,892,000 |
Net Cash Position Past Year | 288,232,000 |
Long Term Debt Past Year | 0 |
Long Term Debt Prior Year | 0 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 307,829,000 |
Total Stockholder Equity Prior Year | 231,337,000 |
Total Stockholder Equity Most Recent Quarter | 552,948,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -116,758,000 |
Free Cash Flow Per Share Twelve Trailing Months | -2.53 |
Free Cash Flow Past Year | -78,563,000 |
Free Cash Flow Prior Year | -98,221,000 |
Options |
|
Put/Call Ratio | 0.03 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.50 |
MACD Signal | -0.69 |
20-Day Bollinger Lower Band | 3.64 |
20-Day Bollinger Middle Band | 12.92 |
20-Day Bollinger Upper Band | 22.20 |
Beta | 2.80 |
RSI | 49.89 |
50-Day SMA | 20.19 |
150-Day SMA | 16.49 |
200-Day SMA | 20.17 |
System |
|
Modified | 11/21/2024 12:41:29 AM EST |